Seeking Alpha

gordon_gekko

gordon_gekko
Send Message
View as an RSS Feed
View gordon_gekko's Comments BY TICKER:
Latest  |  Highest rated
  • Generex to Spin Off Antigen Express to Unlock True Value [View article]
    How'd that spin off go RJS9787?
    Apr 4, 2013. 06:18 PM | Likes Like |Link to Comment
  • Generex: Research For Sale On The Cheap [View article]
    Still pumping this pos like rj steffens, ah Thomas? How much have you lost? Oh, wait, it's only a loss if you sell.
    Mar 13, 2013. 12:31 PM | Likes Like |Link to Comment
  • Generex's Antigen Express Makes Progress In Early Stage Breast Cancer [View article]
    BOOM!!!!! It imploded...lol. thanks Thomas and RJ for the great investment idea!
    Feb 20, 2013. 12:35 PM | Likes Like |Link to Comment
  • Acadia Pharmaceuticals And Galena Biopharma: What A Difference A Trial Design Can Make [View article]
    hey rich, how'd that generex stock work out for ya? You and Trade millionaires yet ?? LOL.......... Gordon G
    Dec 13, 2012. 08:55 AM | Likes Like |Link to Comment
  • 4 Clean Energy Value Stocks I'm Buying Now [View article]
    Beacon Power Corporation (BCON)
    Beacon has been operating their first commercial scale 20MW flywheel energy storage plant since early this year without mishap, achieving full capacity in June. They are set to begin construction of their second 20MW plant later this year, 54% of the $53 million cost of which will be covered by state and federal grants, making the funding of the plant practical even for a company with a high cost of capital like Beacon. If both plants continue the relatively trouble-free operation seen so far, that experience will pave the way for less capital-intensive turn-key sales for flywheel energy storage plants worldwide. I most recently bought shares of BCON for $0.85 on Tuesday.

    CORRECTION: There was a "mishap" at Beacon's Stephentown plant on July 27. Since this undermines my thesis for buying the stock, and there are many other opportunities, I have sold my positions. The fact that this was not mentioned in management's discussion and analysis section of the most recent quarterly report is troubling, in that it shows a lack of commitment to full transparency. I did find it in Item 1A. Risk factors: "In July 2011, one of the 200 flywheels in Stephentown failed. We are currently investigating the root cause and the appropriate corrective action for this failure. Our system operated as designed, and no other equipment was damaged. However, over the life of the plant, if we incur significantly higher than anticipated repair and maintenance costs, it could have a materially adverse effect on our business."

    Thanks to the commenter who brought this to my attention.
    Aug 11, 2011. 11:53 AM | Likes Like |Link to Comment
  • 4 Clean Energy Value Stocks I'm Buying Now [View article]
    eastwickpress.com/news...
    Aug 11, 2011. 11:50 AM | Likes Like |Link to Comment
  • 4 Clean Energy Value Stocks I'm Buying Now [View article]
    you most recently bought at .85 but what have you paid in the past or in other words, how much are you down?
    Aug 11, 2011. 10:13 AM | Likes Like |Link to Comment
  • Generex: Raising Cash, But No Oral-lyn Update [View article]
    digitaltradz is a joke !!!!! It's only for those who have NOTHING to say negative about GNBT or Chuck and/or Richard Steffens will ban you. It's about as one sided as it gets.
    I can't believe that your still bag holding here trade. Remember your Yahoo prediction ??? LOL !!!!
    Jan 31, 2011. 11:01 AM | 3 Likes Like |Link to Comment
  • Generex: Do Development Drug Companies Have No Value? [View article]
    Like you did trademissuh before you posted this ??

    GNBT SUMMARIZATION 30-Jun-07 10:48 am This is a summary of the positive potential of GNBT and when significant events may be occurring to give us longs an idea of what to expect in the near future:

    1. TORC initiated a 12 month target price of $3.00 - $3.50
    back on 9/27/2006. That puts us at that price this
    September which is in 3 months!!!!! This is possible.
    2. Volunteers were selected for the Avian Flu Vaccine back
    in February of this year. We should be hearing
    something about the studies I would say in August which
    puts us at the 6 month mark. We know that this vaccine
    will be a success because Antigen Express knows their
    stuff with synthetic vaccines. Bird Flu is heating up
    again.
    3. Last year in August, Clinical Trials in Greece were
    initiated for the Prostate Cancer vaccine. So, we
    should hear something soon, I am estimating in August
    or September. So, you see, August and September are
    shaping up to be big months for GNBT. That is why
    TORC put a year's target of $3 - $3.50 back in Sept.
    of last year. We are almost there guys.
    4. Jesup and Lamont initiated coverage with a buy and
    price target of $3.25 back in February of this year.
    5. GNBT entered into a deal with the Chinese to study
    a Novel RNAI treatment for cancer back in March of this
    year. We should hear something at the 6 month mark
    which again puts us in September/October. You see
    how things are shaping up?
    6. BIG ONE: GNBT entered a licensing agreement for Oralyn
    with Leosons of the Middle East and approvals will be
    in line for Fall of 2007. Again September/October.
    This is the big Kahuna here guys.
    7. GNBT announced Middle Eastern distribution of Glucose
    Rapidspray back in April of this year. Revenues!!!!!
    8. GNBT announced the treatment of the first breast
    cancer patients in Phase II trials in May of this
    year. We should hear something in November. Not
    that far off. After the blockbuster announcements
    I have mentioned above in Sept/Oct, now we will hear
    about these trials in November. Wow!!
    9. In May of this year, GNBT announced the launch of the
    two new OTC products. More revenues!!
    10. Rodman and Renshaw start coverage on GNBT with a
    price target of $6 over the next year. That could be
    as soon as January of 2008 like 6 months off.
    Things are looking good guys.
    11. Other things to consider: We should see some other
    South American approvals before the end of the year
    for Oralyn and GNBT will begin their Phase III
    studies probably in October. Sept/October is the
    time frame to be looking at for big changes!!!
    Hope this helps everyone as they are watching GNBT
    in the coming months.


    You do remember posting this don't you trade ??
    Oct 1, 2010. 08:59 PM | Likes Like |Link to Comment
  • Generex's Antigen Express: Creating the Next Generation of Cancer Immunotherapy [View article]
    Remember this Trademissuh ???

    GNBT SUMMARIZATION 30-Jun-07 10:48 am This is a summary of the positive potential of GNBT and when significant events may be occurring to give us longs an idea of what to expect in the near future:

    1. TORC initiated a 12 month target price of $3.00 - $3.50
    back on 9/27/2006. That puts us at that price this
    September which is in 3 months!!!!! This is possible.
    2. Volunteers were selected for the Avian Flu Vaccine back
    in February of this year. We should be hearing
    something about the studies I would say in August which
    puts us at the 6 month mark. We know that this vaccine
    will be a success because Antigen Express knows their
    stuff with synthetic vaccines. Bird Flu is heating up
    again.
    3. Last year in August, Clinical Trials in Greece were
    initiated for the Prostate Cancer vaccine. So, we
    should hear something soon, I am estimating in August
    or September. So, you see, August and September are
    shaping up to be big months for GNBT. That is why
    TORC put a year's target of $3 - $3.50 back in Sept.
    of last year. We are almost there guys.
    4. Jesup and Lamont initiated coverage with a buy and
    price target of $3.25 back in February of this year.
    5. GNBT entered into a deal with the Chinese to study
    a Novel RNAI treatment for cancer back in March of this
    year. We should hear something at the 6 month mark
    which again puts us in September/October. You see
    how things are shaping up?
    6. BIG ONE: GNBT entered a licensing agreement for Oralyn
    with Leosons of the Middle East and approvals will be
    in line for Fall of 2007. Again September/October.
    This is the big Kahuna here guys.
    7. GNBT announced Middle Eastern distribution of Glucose
    Rapidspray back in April of this year. Revenues!!!!!
    8. GNBT announced the treatment of the first breast
    cancer patients in Phase II trials in May of this
    year. We should hear something in November. Not
    that far off. After the blockbuster announcements
    I have mentioned above in Sept/Oct, now we will hear
    about these trials in November. Wow!!
    9. In May of this year, GNBT announced the launch of the
    two new OTC products. More revenues!!
    10. Rodman and Renshaw start coverage on GNBT with a
    price target of $6 over the next year. That could be
    as soon as January of 2008 like 6 months off.
    Things are looking good guys.
    11. Other things to consider: We should see some other
    South American approvals before the end of the year
    for Oralyn and GNBT will begin their Phase III
    studies probably in October. Sept/October is the
    time frame to be looking at for big changes!!!
    Hope this helps everyone as they are watching GNBT
    in the coming months.

    Jun 24, 2010. 07:00 PM | Likes Like |Link to Comment
  • Generex's Antigen Express: Creating the Next Generation of Cancer Immunotherapy [View article]
    Hey trademissuh, need I post your predictions for GNBT here? You've been wrong for years now along with RJS with your predictions.
    The Yahoo MB still has your posts over there and you and RJS were completely wrong and still are.
    Apr 15, 2010. 07:04 AM | 1 Like Like |Link to Comment
  • Sorting Out The Street's Misinformation on Generex [View article]
    That's a cell phone - user 475127 !!
    Mar 28, 2010. 09:29 PM | Likes Like |Link to Comment
  • Generex Brouhaha: Big Pharma Is Actually Not So Smart [View article]
    Explain this Thomas....

    Here's another generex joke..

    Generex Establishes Key Strategic Relationships for the Development of a Distribution Network for Generex Oral-lyn(R) Under the FDA's Expanded Access Treatment IND Program.

    In collaboration with Generex, TS BioPharma, Inc. will source, evaluate, and assist in the engagement of suitable clinical sites for the Program and mount a recruitment campaign for the participation in the Program of physicians, nurse practitioners, and patients. TS BioPharma a multi-tiered pharmaceutical development services organization and an innovator in the methods and processes used to minimize time and expense in each level of clinical development.

    Do some DD on TS BioPharma. Find their office and get me an office phone number.
    All I can find is a cell phone number. Kinda fishy huh ?
    Mar 28, 2010. 02:54 PM | 2 Likes Like |Link to Comment
  • Sorting Out The Street's Misinformation on Generex [View article]
    Here's another generex joke..

    Generex Establishes Key Strategic Relationships for the Development of a Distribution Network for Generex Oral-lyn(R) Under the FDA's Expanded Access Treatment IND Program.

    In collaboration with Generex, TS BioPharma, Inc. will source, evaluate, and assist in the engagement of suitable clinical sites for the Program and mount a recruitment campaign for the participation in the Program of physicians, nurse practitioners, and patients. TS BioPharma a multi-tiered pharmaceutical development services organization and an innovator in the methods and processes used to minimize time and expense in each level of clinical development.

    Do some DD on TS BioPharma. Find their office and get me an office phone number>
    Can't be done because they are not real !!!!
    Mar 28, 2010. 02:52 PM | 2 Likes Like |Link to Comment
  • Sorting Out The Street's Misinformation on Generex [View article]
    And people are suppose to believe you (joe smoe) over A writer from The Street.com ?
    He put you in your place didn't he?

    "In a comment posted to last week's Mailbag, RJS9787 wrote, "Interesting take on Generex, Adam. Your two premises are completely false. First there have been numerous peer reviews for Oral-lyn dating back to the early part of this decade... In 2010, the two main independent researchers studying Oral-lyn, Dr. P. Raskin and Dr. P. Pozzilli, published the latest update for Oral-lyn's clinical development and this appeared in the peer-reviewed journal Diabetes, Obesity and Metabolism. All of the studies concluded by showing zero serious adverse effects attributed to Oral-lyn and that buccal spray insulin is non inferior, and often superior, to regular injectable insulin."
    The February 2010 review article on Oral-lyn authored by Raskin and Pozzilli titled "Review of Clinical Trials: Update on Oral Insulin Spray Formulation" is helpful, but not in the way that RJS contends. Far from vindicating Oral-lyn, the article actually demonstrates quite clearly the lack
    An abstract is available for free here but it's best to purchase the entire article, lest you succumb to spin jobs from Generex supporters like RJS.
    Generex has conducted clinical studies of Oral-lyn, but most, if not all, of these trials were poorly designed and enrolled just a handful of patients. Raskin and Pozzilli, in their review article, summarize two studies of Type 2 diabetics conducted in Ecuador that enrolled 21 patients and 23 patients, respectively. Treatment in the studies lasted no more than 10 days. Diabetes patients in the studies were also being treated with other medications, including regular insulin, which makes interpreting results difficult, if not impossible. Other studies of Oral-lyn in Type 1 diabetics reviewed by the authors in the Diabetes, Obesity and Metabolism journal enrolled 18 patients, 10 patients and six patients, respectively.
    Nowhere in the article do Raskin and Pozzilli conclude that Oral-lyn is safe or effective, although they discuss data from the tiny, short studies that appear to show Oral-lyn having a faster onset of action and shorter duration of action when compared to regular insulin given by injection.
    Regular insulin is slow acting and isn't used by diabetics around mealtime, which makes the Oral-lyn data irrelevant.
    Raskin and Pozzilli, in their article, write, "A key limitation to this review is the lack of studies that compare oral insulin spray with rapid-acting analogue insulin; none of the published studies (to date) have provided this comparison. Given the relatively common use of rapid-acting analogues...studies comparing the activity and efficacy of oral insulin spray with these insulin analogues would provide a more robust assessment of the clinical utility of the oral formulation."
    The authors go on to say, "The clinical implications of these findings may be quite significant... However, because of the small number of subjects studied in these trials, it is too early to generalize the effects and benefits of oral insulin spray in larger diabetic populations."
    Generex isn't interested in seriously developing an oral insulin spray. That should be clear to anyone who watches the company pass off studies conducted in Ecuador on less than two-dozen patients as clinically meaningful science. Nonsense! "

    Your just a pumper with a motive where as he is just a writer with NO motive.
    Mar 28, 2010. 12:32 PM | 3 Likes Like |Link to Comment
COMMENTS STATS
17 Comments
11 Likes